A Randomized, Double-blinded, Placebo-controlled Phase II/III Clinical Trial to Evaluate the Efficacy, Safety and Immunogenicity of a Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001 as Booster Vaccination in Adults 18 Years of Age or Older Completed Two-dose or Three-dose Inactivated COVID-19 Vaccine
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- COVID-19
- Sponsor
- Yantai Patronus Biotech Co., Ltd.
- Enrollment
- 18000
- Primary Endpoint
- First occurrence of confirmed symptomatic COVID-19 incidence rate per person-years of follow-up
- Status
- Not Yet Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
The study will be conducted in two phases using a randomized, double-blind, placebo-controlled design. A phase II trial will be initiated to assess the safety of LYB001 as booster shots, and then proceed to a phase III trial to assess the vaccine efficacy (VE) of LYB001 against COVID-19 after an acceptable safety profile, per the judgement of Data and Safety Monitoring Board (DSMB), within 28 days after booster in the phase Ⅱ trial is assessed. After collection of 155 COVID-19 cases, all participants will get unblinded. Participants assigned to the placebo group can choose to receive LYB001 vaccine at their own discretion.
Phase II stage:
The purpose of phase Ⅱ study is to assess the safety of healthy subjects aged 18 years and older who have completed two-dose or three-dose inactivated COVID-19 vaccine for 6-18 months. About 200 age s-stratified subjects aged over 18 years will be randomly assigned to receive the LYB001 or placebo in a 1:1 ratio in the deltoid muscle of the upper arm.
The Phase III study will be initiated after the DSMB confirm that all subjects in Phase II experience acceptable safety profile within 28 days after booster. All subjects in Phase II trial will be required to complete efficacy follow-ups for 12 months along with safety observation, and will be included in the Phase III efficacy analysis set (Phase II data will eventually be combined with Phase III data for statistical analysis, including efficacy and safety data).
Phase III stage:
A total of 17800 participants aged 18 years and older who have completed two-dose or three-dose inactivated COVID-19 vaccine for 6-18 months. The participants will be randomly assigned to the LYB001 booster or placebo booster group in 1:1 ratio according stratification factors of study center and age (18-59 years vs. ≥60 years) , with participants aged ≥ 60 years accounting for over 20 percent of total population.
After booster vaccination, all subjects will be evaluated for protective efficacy and safety, and 1000 subjects (800 subjects aged 18-59 years, and 200 subjects aged ≥60 years) will be enrolled in the subgroup for immunogenicity evaluation (LYB001: Placebo=1:1).
All subjects will be followed up to 12 months after booster vaccination. The entire clinical study will be completed after the pre-defined COVID-19 cases has been achieved and each participant has completed 12-month follow-ups.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Healthy subjects aged 18 years and older, including both males and females;
- •Subjects who agree to participate in this clinical trial voluntarily and sign the informed consent form, are capable of providing valid identification, understanding and complying with the requirements of the clinical protocol.
- •Subjects who have been vaccinated with two-dose or three-dose inactivated COVID-19 vaccine for6-18 months (including boundary values).
- •For female participants of childbearing potential, effective contraception measures should be used within 2 weeks prior to participation in this study and the results of pregnancy test is required to be negative. Participants should voluntarily agree to use effective contraceptive measures from the time of signing the informed consent form to the end of the study (effective contraceptive measures including oral contraceptives (excluding emergency contraceptives), injectable or implantable contraceptives, sustained-release topical contraceptives, hormonal patches, intrauterine device, sterilization, abstinence, condoms (for males), diaphragms, cervical caps, etc.).
Exclusion Criteria
- •Receipt of any COVID-19 prophylactic medication other than inactivated COVID-19 vaccine (e.g., receipt history of any approved or under developing COVID-19 vaccines, or other COVID-19 prophylactic medication, etc.), or previous vaccination history other than other than two- or three-dose inactivated COVID-19 vaccination;
- •Systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg (for subjects with poorly controlled blood pressure), or axillary body temperature ≥ 37.3°C prior to enrolment;
- •Known allergy, or history of anaphylaxis or other serious adverse reactions to vaccines or their excipients;
- •History of severe acute respiratory syndrome (SARS) or Middle East respiratory syndrome (MERS);
- •History of COVID-19, or positive results for SARS-CoV-2 nucleic acid or antigen tests at screening;
- •Receipt of any live attenuated vaccine within 28 days prior to vaccination, and other vaccines such as subunit and inactivated vaccine within 14 days prior to vaccination;
- •Receipt of blood or blood-related products, including immunoglobulins, monoclonal antibodies, within 3 months prior to vaccination; or any planned use during the study period.
- •Subjects with the following diseases:
- •Any acute diseases or acute attacks of chronic diseases within 7 days prior to enrolment；
- •Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.；
Outcomes
Primary Outcomes
First occurrence of confirmed symptomatic COVID-19 incidence rate per person-years of follow-up
Time Frame: 14 days after the booster
Secondary Outcomes
- First occurrence of confirmed severe, critical, and fatal COVID-19 incidence per person-years of follow-up(14 days after the booster)
- Solicited local/systemic adverse events(7 days after the booster)
- Unsolicited adverse events(28 days after the booster)
- Geometric mean titers of neutralizing antibodies against wild-type SARS-CoV-2 and circulating variants of concern, S protein-binding antibodies in immunogenicity subgroup(14days, 28 days after booster, and 3, 6, 12 months after booster)
- Geometric mean fold rises of neutralizing antibodies against wild-type SARS-CoV-2 and circulating variants of concern, S protein-binding antibodies in immunogenicity subgroup(14days, 28 days after booster, and 3, 6, 12 months after booster)
- Seroconversion rates of neutralizing antibodies against wild-type SARS-CoV-2 and circulating variants of concern, S protein-binding antibodies in immunogenicity subgroup(14days, 28 days after booster, and 3, 6, 12 months after booster)